

# Loic Champion

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9528467/publications.pdf>

Version: 2024-02-01

147  
papers

7,238  
citations

61984

43  
h-index

60623

81  
g-index

163  
all docs

163  
docs citations

163  
times ranked

9282  
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review. <i>Cancers</i> , 2022, 14, 172.	3.7	2
2	Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer. <i>Cancers</i> , 2021, 13, 248.	3.7	4
3	The DNA methylation landscape of multiple myeloma shows extensive inter- and inpatient heterogeneity that fuels transcriptomic variability. <i>Genome Medicine</i> , 2021, 13, 127.	8.2	9
4	OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer. <i>European Urology</i> , 2021, 80, 405-414.	1.9	48
5	Intra-abdominal recurrence from colorectal carcinoma: Differences and similarities between local and peritoneal recurrence. <i>Surgical Oncology</i> , 2020, 32, 23-29.	1.6	2
6	Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 3725.	3.7	3
7	DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma. <i>Clinical Epigenetics</i> , 2020, 12, 163.	4.1	9
8	Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal Cancer. <i>Cancers</i> , 2020, 12, 1512.	3.7	4
9	Evaluation of predictor risk factors and calculation of a margin index for ipsilateral invasive recurrence following treatment of DCIS: A 15-year observational study. <i>Breast Journal</i> , 2020, 26, 1067-1068.	1.0	0
10	Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?. <i>Cancers</i> , 2020, 12, 635.	3.7	6
11	Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1205-1211.	5.0	22
12	Abstract P3-08-17: Clinical factors of late recurrence of HR+ early breast cancer after completion of 5 years of aromatase inhibitor and development of a prognostic tool. A study of 1496 women of the ICO database. , 2020, , .		0
13	Abstract P1-19-19: Treatments and outcome in older versus younger women with HER2-positive metastatic breast cancer in the multicenter national observational ESME database. , 2020, , .		0
14	Preliminary results of a <sup>68</sup> Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making. <i>Prostate</i> , 2019, 79, 1514-1522.	2.3	25
15	The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME). <i>BMJ Open</i> , 2019, 9, e023568.	1.9	42
16	Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07). <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1061-1067.	0.8	36
17	Reoxygenation during radiotherapy in intermediate-risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, 16-19.	0.6	23
18	Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4) Tj ETQq0 02rgBT /Overlock 10		

#	ARTICLE	IF	CITATIONS
19	68Ga-PSMA-1 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes. <i>Prostate</i> , 2019, 79, 454-461.	2.3	14
20	RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1092-1092.	1.6	20
21	Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15027-e15027.	1.6	2
22	Prostate cancer with oligometastatic relapse: Combining stereotactic ablative radiotherapy and durvalumab, a randomized phase II trial (POSTCARD - GETUG-P13).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5088-TPS5088.	1.6	5
23	Model predicting the ypN0 status after good response to chemoradiotherapy in rectal cancer. <i>American Journal of Surgery</i> , 2018, 216, 438-443.	1.8	4
24	Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 559-566.	2.5	26
25	Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer. <i>Supportive Care in Cancer</i> , 2018, 26, 81-89.	2.2	43
26	Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients. <i>PLoS ONE</i> , 2018, 13, e0194173.	2.5	24
27	Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study. <i>Cancer Medicine</i> , 2018, 7, 4023-4035.	2.8	39
28	An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1112-TPS1112.	1.6	3
29	Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET/CT: a pilot study. <i>Oncotarget</i> , 2018, 9, 10005-10015.	1.8	16
30	PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4) Tj ETQqO 0 0 r gBT /Overlock 10 Tf 5 TPS3622-TPS3622.	2.6	10
31	Dynamic conformal arc radiosurgery for arteriovenous malformations: Outcome and influence of clinical and dosimetrical data. <i>Radiotherapy and Oncology</i> , 2017, 123, 251-256.	0.6	5
32	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45.	4.6	33
33	Logic programming reveals alteration of key transcription factors in multiple myeloma. <i>Scientific Reports</i> , 2017, 7, 9257.	3.3	20
34	An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1117-TPS1117.	1.6	11
35	Combined abiraterone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP.. <i>Journal of Clinical Oncology</i> , 2017, 35, 45-45.	1.6	1
36	Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. <i>PLoS ONE</i> , 2017, 12, e0183841.	2.5	22

#	ARTICLE	IF	CITATIONS
37	Initial FDG-PET/CT predicts survival in adults Ewing sarcoma family of tumors. <i>Oncotarget</i> , 2017, 8, 77050-77060.	1.8	13
38	Can We Spare the Pancreas and Other Abdominal Organs at Risk? A Comparison of Conformal Radiotherapy, Helical Tomotherapy and Proton Beam Therapy in Pediatric Irradiation. <i>PLoS ONE</i> , 2016, 11, e0164643.	2.5	18
39	Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1473-1479.	2.0	9
40	Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study. <i>Clinical Colorectal Cancer</i> , 2016, 15, e165-e174.	2.3	9
41	Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan. <i>Radiotherapy and Oncology</i> , 2016, 119, 229-235.	0.6	29
42	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 4350-4355.	7.0	38
43	High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 840-847.	0.8	18
44	Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1849-1856.	6.4	3
45	OLIGOPELVIS " GETUG P07, a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer: Preplanned analysis of acute toxicity.. <i>Journal of Clinical Oncology</i> , 2016, 34, 173-173.	1.6	0
46	High-Resolution Whole-Genome Copy Number Profiling Identifies High-Risk and Low-Risk Patients with Mantle Cell Lymphoma, a Result of the Lyma-Genomic Project Conducted on Behalf the Lysa Group. <i>Blood</i> , 2016, 128, 1745-1745.	1.4	6
47	Hypofractionated irradiation in elderly patients with breast cancer after breast conserving surgery and mastectomy : Analysis of 205 cases. <i>Radiation Oncology</i> , 2015, 10, 161.	2.7	16
48	OLIGOPELVIS " GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer. <i>BMC Cancer</i> , 2015, 15, 646.	2.6	44
49	Gene-expression signature functional annotation of breast cancer tumours in function of age. <i>BMC Medical Genomics</i> , 2015, 8, 80.	1.5	6
50	Early Assessment of Metabolic Response by 18F-FDG PET During Concomitant Radiochemotherapy of Non-Small Cell Lung Carcinoma Is Associated With Survival. <i>Clinical Nuclear Medicine</i> , 2015, 40, e215-e221.	1.3	29
51	Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up. <i>Frontiers in Medicine</i> , 2015, 2, 46.	2.6	16
52	Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with 18F-Choline PET/CT in Prostate Cancer. <i>Frontiers in Medicine</i> , 2015, 2, 67.	2.6	6
53	Postoperative interstitial brachytherapy for resectable squamous cell carcinoma of the tongue. <i>Brachytherapy</i> , 2015, 14, 71-76.	0.5	14
54	Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. <i>Breast Cancer Research</i> , 2015, 17, 43.	5.0	248

#	ARTICLE	IF	CITATIONS
55	Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 2936-2946.	3.8	61
56	Abstract P2-01-01: Sentinel node surgery after neoadjuvant chemotherapy in patient with axillary node involvement: The French GANEA 2 prospective multi-institutional trial. , 2015, , .		1
57	Abstract P2-04-07: Gene-expression molecular subtyping of immunohistochemistry-typed triple-negative breast cancer tumours. , 2015, , .		0
58	Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study. <i>Annals of Surgical Oncology</i> , 2014, 21, 3621-3627.	1.5	47
59	Laparoscopic Sentinel Lymph Node Versus Hyperextensive Pelvic Dissection for Staging Clinically Localized Prostate Carcinoma: A Prospective Study of 200 Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 753-758.	5.0	26
60	Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma. <i>BMC Cancer</i> , 2014, 14, 606.	2.6	23
61	18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1501-1510.	6.4	14
62	Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics. <i>Oncologie</i> , 2014, 16, 267-276.	0.7	2
63	Prognostic Value and Clinical Impact of 18FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy. <i>Frontiers in Medicine</i> , 2014, 1, 54.	2.6	17
64	Efficacy and safety of FOLFIRINOX in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 305-305.	1.6	5
65	Totally implantable venous access port: A prospective long-term study of early and late complications in adult patients with cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20635-e20635.	1.6	0
66	FOLFIRINOX in first-line metastatic pancreatic cancer regimen (FLMPC): What profile of patients take a real advantage? Real world cohort from cancer observatory from Brittany and Pays de la Loire areas.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15204-e15204.	1.6	1
67	A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus. <i>Blood</i> , 2014, 124, 2057-2057.	1.4	0
68	Important Prognostic Impact of Early Monocytes Recovery after Reduced Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults. <i>Blood</i> , 2014, 124, 5923-5923.	1.4	0
69	Margin Width Should Not Still Enforce a Systematic Surgical Re-excision in the Conservative Treatment of Early Breast Infiltrative Ductal Carcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 3831-3838.	1.5	12
70	Pure tubular carcinoma of the breast and sentinel lymph node biopsy: A retrospective multi-institutional study of 234 cases. <i>European Journal of Surgical Oncology</i> , 2013, 39, 248-254.	1.0	22
71	Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer. <i>Radiation Oncology</i> , 2013, 8, 53.	2.7	16
72	bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database: the <i>Journal of Biological Databases and Curation</i> , 2013, 2013, bas060-bas060.	3.0	211

#	ARTICLE	IF	CITATIONS
73	Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du Myélome Experience. <i>Journal of Clinical Oncology</i> , 2013, 31, 2806-2809.	1.6	103
74	CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2013, 73, 6711-6721.	0.9	91
75	Low Level Of NF-Kb Activity Is Associated With Higher Response Rate To Bortezomib-Based Induction Therapy In Patients With Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 3106-3106.	1.4	1
76	Efficacy and safety of FOLFIRINOX in patients with pancreatic metastatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 248-248.	1.6	1
77	Early dynamic transcriptomic changes during preoperative radiotherapy in patients with rectal cancer: A feasibility study. <i>World Journal of Gastroenterology</i> , 2013, 19, 3249.	3.3	31
78	Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. <i>Leukemia</i> , 2012, 26, 158-159.	7.2	44
79	Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival. <i>Journal of Clinical Oncology</i> , 2012, 30, 1949-1952.	1.6	198
80	Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1185-1192.	5.0	74
81	Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: A multicentric 2004 national PHRC study. <i>International Journal of Oncology</i> , 2012, 41, 92-104.	3.3	8
82	Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study. <i>International Journal of Cancer</i> , 2012, 131, 426-437.	5.1	64
83	Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 291-299.	6.4	19
84	bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 765-775.	2.5	308
85	Clinical Characteristics, Chromosomal Abnormalities and Outcomes in Very Elderly Patients with Multiple Myeloma: The IFM Experience. <i>Blood</i> , 2012, 120, 204-204.	1.4	3
86	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. <i>Blood</i> , 2012, 120, 906-906.	1.4	5
87	Prospective determination of long-term toxicity and quality of life (QoL) of patients with prostate cancer after intensity-modulated radiotherapy (IMRT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 151-151.	1.6	0
88	Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases. <i>European Journal of Surgical Oncology</i> , 2011, 37, 971-977.	1.0	16
89	Étude de faisabilité du ganglion sentinelle dans le cancer de la prostate par échographie: premiers résultats. <i>Medecine Nucleaire</i> , 2011, 35, 461-469.	0.2	0
90	Antibody Responses to NY-ESO-1 in Primary Breast Cancer Identify a Subtype Target for Immunotherapy. <i>PLoS ONE</i> , 2011, 6, e21129.	2.5	20

#	ARTICLE	IF	CITATIONS
91	Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. Blood, 2011, 117, 2009-2011.	1.4	115
92	FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1029-1036.	6.4	51
93	Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer. BMC Cancer, 2011, 11, 98.	2.6	13
94	c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Molecular Cancer, 2011, 10, 110.	19.2	38
95	Prognostic factors for T1â€“T2 squamous cell carcinomas of the mobile tongue: A retrospective cohort study. Head and Neck, 2011, 33, 928-934.	2.0	27
96	High-Dose-Rate Brachytherapy for Nonâ€“Small-Cell Lung Carcinoma: A Retrospective Study of 226 Patients. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1112-1116.	0.8	49
97	Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica, 2010, 95, 1973-1976.	3.5	124
98	Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1270-1278.	6.4	42
99	Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. Journal of Neuro-Oncology, 2010, 97, 311-322.	2.9	169
100	No Impairment of Quality of Life 18 Months After High-Dose Intensity-Modulated Radiotherapy for Localized Prostate Cancer: A Prospective Study. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1053-1059.	0.8	36
101	Videotaped simulated interviews to improve medical students' skills in disclosing a diagnosis of cancer. Psycho-Oncology, 2010, 19, 975-981.	2.3	43
102	Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity. Cancer Science, 2010, 101, 889-897.	3.9	15
103	Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p). Journal of Clinical Oncology, 2010, 28, 4630-4634.	1.6	383
104	Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Advanced Breast Cancer: Results of Ganglion Sentinelle et ChimiothÃ©rapie Neoadjuvante, a French Prospective Multicentric Study. Journal of Clinical Oncology, 2009, 27, 726-732.	1.6	220
105	Folate Supplementation Limits the Aggressiveness of Glioma via the Remethylation of DNA Repeats Element and Genes Governing Apoptosis and Proliferation. Clinical Cancer Research, 2009, 15, 3519-3529.	7.0	62
106	Prognostic Significance of Copy-Number Alterations in Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 4585-4590.	1.6	258
107	Molecular characterization of the response to chemotherapy in conventional osteosarcomas: Predictive value of HSD17B10 and IFITM2. International Journal of Cancer, 2009, 125, 851-860.	5.1	36
108	A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Breast Cancer Research and Treatment, 2009, 116, 509-520.	2.5	14

#	ARTICLE	IF	CITATIONS
109	Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1813-1821.	6.4	111
110	Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. <i>British Journal of Cancer</i> , 2009, 101, 166-173.	6.4	61
111	Molecular screening of interleukin-6 gene promoter and influence of $\sim 174G/C$ polymorphism on breast cancer. <i>Cytokine</i> , 2009, 47, 214-223.	3.2	26
112	Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 491-501.	2.5	34
113	Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. <i>British Journal of Cancer</i> , 2008, 98, 1993-1998.	6.4	64
114	Osteoclasts support the survival of human plasma cells in vitro. <i>International Immunology</i> , 2008, 20, 775-782.	4.0	36
115	Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome. <i>Journal of Clinical Oncology</i> , 2008, 26, 4798-4805.	1.6	361
116	Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. <i>Haematologica</i> , 2008, 93, 390-397.	3.5	45
117	Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. <i>Haematologica</i> , 2008, 93, 471-472.	3.5	130
118	In Myeloma, the Prognostic Impact of Hyperdiploidy Is Mainly Related to the Gain of Chromosome 5. <i>Blood</i> , 2008, 112, 632-632.	1.4	0
119	Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4590-4597.	3.6	89
120	La radio-immunothérapie par ciblage des tumeurs solides: une démarche pluridisciplinaire. <i>Medecine Nucleaire</i> , 2007, 31, 498-505.	0.2	1
121	PD5-3-2: Prognostic value of the number of examined lymph nodes in totally resected Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S479.	1.1	0
122	Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. <i>Proteomics</i> , 2006, 6, 1963-1975.	2.2	89
123	High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 834, 170-177.	2.3	36
124	Brown fat in breast cancer patients: analysis of serial 18F-FDG PET/CT scans. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 785-791.	6.4	87
125	Randomized clinical trial comparing axillary padding with closed suction drainage for the axillary wound after lymphadenectomy for breast cancer. <i>British Journal of Surgery</i> , 2006, 93, 820-824.	0.3	45
126	Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti-Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 1705-1711.	1.6	231



#	ARTICLE	IF	CITATIONS
127	Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2006, 24, 5366-5372.	1.6	290
128	Gene Expression Profiling Comparison between the Major Mature B-Cell Neoplasms and Their Normal Cellular and Anatomic Counterparts: Identification of Candidate Genes Potentially Involved in Lymphomagenesis.. <i>Blood</i> , 2006, 108, 2375-2375.	1.4	0
129	Molecular Prognosis in Multiple Myeloma: The IFM Experience.. <i>Blood</i> , 2006, 108, 3491-3491.	1.4	1
130	Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and <sup>131</sup> I-labeled bivalent hapten in a phase I optimization clinical trial. <i>Journal of Nuclear Medicine</i> , 2006, 47, 247-55.	5.0	88
131	Gene Expression Profiles Discriminate between Pathological Complete Response and Resistance to Neoadjuvant FEC100 in Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2006, 3, 89-95.	2.0	1
132	Interstitial brachytherapy of periorificial skin carcinomas of the face: A retrospective study of 97 cases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 753-757.	0.8	73
133	The Impact of Nonvisualization of Sentinel Nodes on Lymphoscintigraphy in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2005, 12, 533-538.	1.5	28
134	Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6077-6084.	3.6	361
135	Post-operative care and patient satisfaction after ambulatory surgery for breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2005, 31, 495-499.	1.0	58
136	G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. <i>British Journal of Cancer</i> , 2004, 90, 189-193.	6.4	56
137	Validation of axillary sentinel lymph node detection in the staging of early lobular invasive breast carcinoma. <i>Cancer</i> , 2004, 100, 935-941.	4.1	27
138	Learning curve for the detection of axillary sentinel lymph node in breast cancer. <i>European Journal of Surgical Oncology</i> , 2003, 29, 426-433.	1.0	40
139	Lymphoscintigraphy in the Sentinel Lymph Node Technique for Breast Tumor: Value of Early and Late Images for the Learning Curve. <i>Medical Principles and Practice</i> , 2003, 12, 17-22.	2.4	1
140	Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 267-74.	4.1	31
141	Long-term complications of total body irradiation in adults. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 125-131.	0.8	108
142	High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity. <i>Biomedical Applications</i> , 2001, 762, 203-209.	1.7	20
143	Genetic polymorphism at the glutathione S-transferase (GST) P1 locus is a breast cancer risk modifier. <i>International Journal of Cancer</i> , 2001, 91, 334-339.	5.1	45
144	Salvage extended-field irradiation in follicular non-Hodgkin's lymphoma after failure of chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 47, 735-738.	0.8	8

#	ARTICLE	IF	CITATIONS
145	Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1487-1493.	2.1	107
146	Antithyroid drugs and Graves' disease - prospective randomized assessment of long-term treatment. <i>Clinical Endocrinology</i> , 1999, 50, 127-132.	2.4	104
147	Clinical and statistical evaluation of self-monitoring blood glucose meters. <i>Diabetes Care</i> , 1998, 21, 1919-1924.	8.6	65